These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39430335)

  • 1. Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.
    Zhao J; Lu Y; Wang Z; Wang H; Zhang D; Cai J; Zhang B; Zhang J; Huang M; Pircher A; Patel KH; Ke H; Song Y
    Transl Lung Cancer Res; 2024 Sep; 13(9):2395-2410. PubMed ID: 39430335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
    Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
    Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].
    Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
    Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
    J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
    [No Abstract]   [Full Text] [Related]  

  • 5. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer.
    Cao L; Che X; Qiu X; Li Z; Yang B; Wang S; Hou K; Fan Y; Qu X; Liu Y
    Cancer Manag Res; 2019; 11():6125-6138. PubMed ID: 31308749
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer.
    Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2015-2027. PubMed ID: 36738309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
    Liu KJ; Li HR; Tan QQ; Jiang T; Peng KC; Chen HJ; Zhou Q; Zhang XC; Zheng Z; Chen SY; Zheng X; Zheng HB; Mao BB; Gong LL; Chen XW; Wu W; Wu YL; Jia J; Yang JJ
    Lung Cancer; 2024 Sep; 195():107933. PubMed ID: 39191079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
    Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.
    Berthe J; Poudel P; Segerer FJ; Jennings EC; Ng F; Surace M; Andoni A; Testori M; Saraiya M; Vuko M; Hessel H; Heininen-Brown M; Blando J; Jones EV; Willis SE; Galon J; van de Ven R; de Gruijl TD; Angell HK
    Front Immunol; 2024; 15():1422206. PubMed ID: 39376565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Density of tertiary lymphoid structures and their correlation with prognosis in non-small cell lung cancer.
    Xin S; Wen S; He P; Zhao Y; Zhao H
    Front Immunol; 2024; 15():1423775. PubMed ID: 39192984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infiltration of CD8
    Hao J; Wang H; Song L; Li S; Che N; Zhang S; Zhang H; Wang J
    Int J Clin Exp Pathol; 2020; 13(5):880-888. PubMed ID: 32509058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.
    Wessel RE; Ageeb N; Obeid JM; Mauldin I; Goundry KA; Hanson GF; Hossain M; Lehman C; Gentzler RD; Wages NA; Slingluff CL; Bullock TNJ; Dolatshahi S; Brown MG
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.
    Peng H; Wu X; Liu S; He M; Xie C; Zhong R; Liu J; Tang C; Li C; Xiong S; Zheng H; He J; Lu X; Liang W
    Clin Transl Med; 2023 Jan; 13(1):e1155. PubMed ID: 36588094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.